What the company does
Dongwha Pharm makes prescription and over-the-counter medicines, medical devices, and distributes pharmaceutical products to hospitals, pharmacies, and other healthcare buyers across South Korea and overseas.
Listed on KOSPI, South Korea's main stock exchange, it operates through several business lines: a core pharmaceuticals division, a medical-device manufacturing subsidiary, a pharmaceutical distribution chain, and a small financial services unit. Pharmaceuticals account for the largest share of its consolidated revenue, with medical-device manufacturing and drug distribution making up most of the remainder.
Summary is AI-generated and may contain errors · figures from DART filings
Daily close, KRW. Source: KRX via FinanceDataReader.
Financials
Source: DART · FY ending Dec · latest FY2025Revenue
- FY2023US$261.7M
- FY2024US$336.9M
- FY2025US$359.7M
Operating profit
- FY2023US$13.6M
- FY2024US$9.7M
- FY2025US$186.1K
Net income
- FY2023US$20.5M
- FY2024US$1.6M
- FY2025US$2.8M
Key ratios (FY2025)
Why it matters · Context, not a recommendation
Its medical-device subsidiary, Medissey, applies interdisciplinary engineering, combining clinical medicine with electrical, mechanical, materials, and optical technologies, to design and manufacture its products.